Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2852273 | 1.00 | REN (0.40) | RENNPC1RAB9ATP53MAPT | |
| SCHEMBL2850917 | 0.90 | REN (0.38) | RENTP53MAPTSMN1; SMN2DPP4 | |
| SCHEMBL3563341 | 0.90 | REN (0.38) | RENTP53MAPTSMN1; SMN2DPP4 | |
| SCHEMBL3563340 | 0.90 | REN (0.38) | RENTP53MAPTSMN1; SMN2DPP4 | |
| SCHEMBL2848019 | 0.89 | REN (0.42) | RENNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL2849335 | 0.88 | REN (0.46) | RENNPC1RAB9ATP53GRM5 | |
| SCHEMBL4746368 | 0.88 | REN (0.44) | RENNPC1RAB9ATP53MAPT | |
| SCHEMBL4746364 | 0.88 | REN (0.44) | RENNPC1RAB9ATP53MAPT | |
| SCHEMBL2849337 | 0.88 | REN (0.46) | RENNPC1RAB9ATP53GRM5 | |
| SCHEMBL5610964 | 0.85 | REN (0.46) | RENNPC1RAB9AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130471-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-05-27 | — | — | US | disclosed |
| WO-2008124582-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130471-A1 | Renin Inhibitors | ACE, REN, DNPEP | REN 2/4885NPC1 1257/4885RAB9A 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.